Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  BG ControlType 2 DiabetesGLP-1Issue 731GLP-1 Special Editions June 2014GLP-1 Special Editions Summer 2014

AACE: Dulaglutide Predicts HBA1c with Fasting Blood Glucose at 2 Weeks

A study conducted in patients with type 2 diabetes receiving dulaglutide has shown that fasting blood glucose levels 2 weeks after beginning treatment are predictive of long-term glucose control as measured by HbA1c 6 months later.... 

Advertisement

The results are based on post hoc analyses of 2 double-blinded, randomized phase III studies, AWARD-1 and AWARD-5. The AWARD-1 study compared the safety and efficacy of placebo, dulaglutide and exenatide in patients with type 2 diabetes on metformin and pioglitazone. The AWARD-5 study compared the safety and efficacy of placebo, dulaglutide and sitagliptin in patients with type 2 diabetes on metformin.

The primary outcome measure was reduction of HbA1c from baseline to 26 weeks (AWARD-1) or 52 weeks (AWARD-5). Both doses of dulaglutide examined in these studies (0.75 mg and 1.5 mg) significantly reduced HbA1c compared to the respective comparison drugs.

In AWARD-5, 3 categories of fasting blood glucose levels defined at baseline: low (less than 142 mg/dL), intermediate (between 142 and 185 mg/dL) and high (more than 185 mg/dL). At baseline, mean fasting blood glucose was 176 mg/dL. Patients were roughly evenly distributed in each group; 33% (n = 99) were in the low group, 32% (n = 97) in the intermediate group, and 36% (n = 108) in the high group. After two weeks of treatment with 1.5 mg dulaglutide, mean fasting blood glucose was 129 mg/dL and an increased number of patients were in the low group: 68% (n = 208) in the low group, 21% (n = 64) in the intermediate group, and 11% (n = 32) in the high group.

At baseline, the mean HbA1c was 8.1% (n = 304). At week 26 of the study, mean HbA1c was 6.9%. Fasting blood glucose at week 2 was strongly associated with achieving an HbA1c of <7.0% at week 26. A greater number of patients in the low category at week 2 achieved an A1c of <7.0% at week 26. The AWARD-1 data analysis produced similar results.

George Grunberger, MD, of the Grunberger Diabetes Institute, in Bloomfield Hills, Michigan, who published the findings added that, "We found out in the two studies that one could predict the eventual glycemic improvement by dulaglutide already after examining fall in fasting plasma glucose levels after 2 weeks." "If confirmed in other studies, clinicians could predict responders early on and perhaps decide whether to continue dulaglutide therapy or look for another modality much sooner than 8-10 weeks."

Practice Pearls:
  • Dulaglutide has shown that fasting blood glucose levels 2 weeks after beginning treatment are predictive of long-term glucose control
  • The eventual glycemic improvement by dulaglutide could be predicted after examining fall in fasting plasma glucose levels after 2 weeks.
  • This is preliminary information and needs to be studied further.

The findings were presented at the American Association of Clinical Endocrinologists annual meeting held from May 14th to 18th in Las Vegas, Nevada. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2014 and appeared in  BG ControlType 2 DiabetesGLP-1Issue 731GLP-1 Special Editions June 2014GLP-1 Special Editions Summer 2014

Past five issues: Issue 796 | Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 | Diabetes Clinical Mastery Series Issue 254 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
Soybean Oil Causes More Obesity and Diabetes Than Fructose
Posted August 20, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015
What A Can of Coca-Cola Really Does To Your Body
Posted August 20, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients have reached goal for A1c, BP and cholesterol?

CME/CE of the Week
Vickie Driver, DPM, MS, FACFAS

Category: Wound Care
Credits: 1.0